Hwang, Seung Rim Kim, Kwangmeyung 2024-01-20T10:34:39Z 2024-01-20T10:34:39Z 2021-09-05 2014-01 0253-6269 https://pubs.kist.re.kr/handle/201004/127268 The development of drugs to treat disorders of the central nervous system (CNS) faces difficulties in achieving penetration of a drug through the blood-brain barrier (BBB) and allowing the drug to reach its intended target in the brain. There have been strategies to improve drug delivery to the brain through endogenous transport pathways such as passive diffusion, endocytosis, and active transport. Among various strategies, nano-enabled delivery systems offer a promising solution to improve the uptake and targeted delivery of drugs into the brain. Various nanocarriers including liposomes, bolaamphiphiles and nanoparticles can be used as a means to encapsulate drugs, either alone or in combination with targeting ligands. Moreover, most of materials used in nanocarrier fabrication are both biodegradable and biocompatible, thereby increasing the clinical utility of them. Here, we review the possibility to employ nano-enabled materials for delivery of drug across the BBB and the recent advances in nanotechnologies for therapy of the CNS diseases. English PHARMACEUTICAL SOC KOREA CEREBROVASCULAR ENDOTHELIAL-CELLS DRUG-DELIVERY TARGETED DELIVERY NANOPARTICLES RECEPTOR GLIOMA TRANSPORT SURFACE TUMOR RMP-7 Nano-enabled delivery systems across the blood-brain barrier Article 10.1007/s12272-013-0272-6 1 ARCHIVES OF PHARMACAL RESEARCH, v.37, no.1, pp.24 - 30 ARCHIVES OF PHARMACAL RESEARCH 37 1 24 30 scie scopus kci ART001902525 000329094700004 2-s2.0-84892925252 Chemistry, Medicinal Pharmacology & Pharmacy Pharmacology & Pharmacy Review CEREBROVASCULAR ENDOTHELIAL-CELLS DRUG-DELIVERY TARGETED DELIVERY NANOPARTICLES RECEPTOR GLIOMA TRANSPORT SURFACE TUMOR RMP-7 Central nervous system Blood-brain barrier Nanotechnology Nano-enabled delivery Receptor-mediated transcytosis